South Korea-based Lunit Inc (KRX:328130), a provider of AI solutions for cancer diagnostics and therapeutics, and US biopharmaceutical oncology company Summit Therapeutics Inc (NASDAQ:SMMT) announced on Friday a research agreement to evaluate the use of Lunit SCOPE IO, Lunit's AI-powered pathology platform, for tumour microenvironment analysis in support of Summit's immuno-oncology development programmes with ivonescimab.

This effort will focus on applying Lunit SCOPE IO to haematoxylin and eosin-stained (H&E) whole-slide images to characterise tumour microenvironment features. The companies aim to explore how AI-powered pathology analysis can support biomarker discovery, patient stratification or selection, and a deeper biological understanding of response to ivonescimab therapies.

Summit is developing ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody, in several solid tumours. Lunit SCOPE IO is designed to support immuno-oncology research and biomarker development through AI-powered analysis of H&E slides, enabling scalable assessment of tumour microenvironment features without requiring additional stains or assays.

Lunit and Summit expect the work to generate tumour microenvironment insights that may inform future translational research, exploratory biomarker strategies, and clinical development planning.